With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short period of time. Currently active in both the UK and Europe, EUSA is set to further expand internationally, notably in the USA. Its founder and executive chairman Bryan Morton shares some of his plans for the company, while also elaborating on his experience as a ‘serial entrepreneur’ and his thoughts on what needs to happen to enable Britain to nurture and maintain its locally developed biotech companies.
Can you please introduce yourself, your career path and experience in the healthcare sector?
"I really believe in the LSIS. I think it is something the UK is capable of delivering and something that should be a clear priority for the industry and government."
